Published in Mental Health Business Week, April 8th, 2006
Forty-nine patients with ADHD completed the randomized, double-blind, placebo-controlled, 2-way crossover design performed at 7 U.S. sites. Cortex undertook this phase IIa clinical trial to assess both the dose of drug required and the effectiveness of CX717 in an adult ADHD population. The primary outcome measure was the ADHD Rating Scale (ADHD-RS) which evaluates both the inattentiveness and hyperactivity symptoms.
The overall ADHD-RS score showed a positive trend in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week